< 生产厂家 价格 >

西尼地平

西尼地平用途

Cilnidipine(FRC8653)是L型和N型钙离子阻断剂,有降压,神经保护活性。
点击显示

西尼地平名称

[ CAS 号 ]:
132203-70-4

[ 中文名 ]:
西尼地平

[ 英文名 ]:
Cilnidipine

[中文别名 ]:

[英文别名 ]:

西尼地平生物活性

[ 描述 ]:

Cilnidipine(FRC8653)是L型和N型钙离子阻断剂,有降压,神经保护活性。

[ 相关类别 ]:

信号通路 >> 跨膜转运 >> 钙通道
研究领域 >> 心血管疾病

[参考文献]

[1]. Masuda T, Ogura MN, Moriya T, et al. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. Cardiovasc Ther. 2011 Feb;29(1):46-53. doi: 10

[2]. Morimoto S, Yano Y, Maki K, Iwasaka T. Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens. 2007 Oct;25(10):2178-83.

[3]. Takahara A, Konda T, Enomoto A, Kondo N. Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model. Biol Pharm Bull. 2004 Sep;27(9):1388-91.

[4]. Murai Y, Uneyama H, Ishibashi H et al. Preferential inhibition of L- and N-type calcium channels in the rat hippocampal neurons by cilnidipine. Brain Res. 2000 Jan 31;854(1-2):6-10.


[相关活性小分子]

硫酸新霉素 | 硝苯地平 | 氯化乙酰胆碱； 乙酰氯化胆碱 | 离子霉素 | (S)-2,6-二甲基-5-硝基-4-(2-三氟甲基)苯基)-1,4-二氢吡啶-3-甲酸甲酯 | 尼莫地平 | 米贝拉地尔 | 左乙拉西坦 | CDN1163 | 丹曲林钠 | 毒胡萝卜素 | 氟芬那酸 | ABT-639 | N-(2,6-二甲基苯基)-2-(4-(2-羟基-3-(2-甲氧基苯氧基)-丙基)哌嗪-1-基)乙酰胺 二盐酸盐 | 色甘酸钠

西尼地平物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
652.6±55.0 °C at 760 mmHg

[ 熔点 ]:
97-99°C

[ 分子式 ]:
C27H28N2O7

[ 分子量 ]:
492.520

[ 闪点 ]:
348.5±31.5 °C

[ 精确质量 ]:
492.189636

[ PSA ]:
119.68000

[ LogP ]:
5.36

[ 外观性状 ]:
黄色结晶固体

[ 蒸汽压 ]:
0.0±2.0 mmHg at 25°C

[ 折射率 ]:
1.592

[ 储存条件 ]:
Store at +4°C

西尼地平MSDS

详细MSDS(安全技术说明书)

西尼地平毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
US7975550
CHEMICAL NAME :
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester, (E)-(+-)-
CAS REGISTRY NUMBER :
132203-70-4
LAST UPDATED :
199712
DATA ITEMS CITED :
13
MOLECULAR FORMULA :
C27-H28-N2-O7
MOLECULAR WEIGHT :
492.57

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4412 mg/kg
TOXIC EFFECTS :
Skin and Appendages - hair
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
426 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Liver - other changes Skin and Appendages - hair
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1845 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Liver - other changes Skin and Appendages - hair
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1683,1992
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1689,1992 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9 gm/kg/90D-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - changes in sodium Related to Chronic Data - death Related to Chronic Data - changes in ovarian weight
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1693,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
9125 mg/kg/1Y-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Related to Chronic Data - death Related to Chronic Data - changes in ovarian weight
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1797,1992 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
624 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - live birth index (measured after birth)
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1975,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
7050 mg/kg
SEX/DURATION :
male 9 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1905,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1100 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1925,1992
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
28 gm/kg
SEX/DURATION :
male 9 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 20(Suppl 7),S1905,1992
点击显示

西尼地平安全信息

[ 符号 ]:

GHS05

[ 信号词 ]:
Danger

[ 危害声明 ]:
H318

[ 警示性声明 ]:
P280-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
R41

[ 安全声明 (欧洲) ]:
S26;S39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
US7975550

[ 海关编码 ]:
2933399090

西尼地平制备

化合物(I)和3-氨基丁烯酸甲酯反应，得到产物。

2. 乙酰乙酸-2-甲氧基乙酯的制备

在反应瓶中加入乙二醇单甲醚79ml(1mol) 和乙胺0.5ml,搅拌,升温至75~80 ºC ,滴加双烯酮84g(1mol),加毕,在同温度下搅拌3h.减压蒸馏,收集110~117 ºC/1.87kPa,馏分,得无色透明液体乙酰乙酸-2-甲氧基乙酯152g,收率95%.

3. 乙酰乙酸肉桂酯的制备

在反应瓶中加入肉桂醇134g(1mol)和乙胺1ml,开搅拌升温至80~85ºC,滴加双烯酮84g(1mol)加毕,在同温度下搅拌3h.TLC跟踪反应[展开剂:甲苯/乙酸乙酯(10:1)].减压蒸除低沸物,得乙酰乙酸肉桂酯209.4g,收率95.6%.

4. 2-(3-硝基亚秝基)乙酰乙酸-2-甲氧基乙酯的制备

在反应瓶中加入乙酰乙酸-2-甲氧基乙酯80g(0.5mol),搅拌下用冰盐浴冷却,慢慢加入H2SO4 1ml,搅匀后加入间硝基苯甲醛75.5g(0.5mol),室温下搅拌6h.析出晶体,放置过夜$抽滤,滤饼用95%乙醇重结晶#得2-(3-硝基亚秝基)乙酰乙酸-2-甲氧基乙酯113.7g,收率77.6%,mp66~67ºC.

5. 3-氨基-2-丁烯酸肉桂酯的制备

在反应瓶中加入乙酰乙酸肉桂酯43.6g(0.2mol),于5ºC以下通氨气,通氨气过程中内温控制不超过10ºC ,反

应4h.加入适量无水乙醇,搅拌至溶,于冰箱中冷却析晶,抽滤,滤饼真空干燥,得淡黄色针状晶体3-氨基-2-丁烯酸肉桂酯36.5g,收率95%.

6. 西尼地平的合成

在反应瓶中加入2-(3-硝基亚秝基)乙酰乙酸-2-甲氧基乙酯58.6g(0.2mol)和3-氨基-2-丁烯酸肉桂酯43.4g(0.2mol),于110~120搅拌3h.加入无水乙醇50ml、活性炭0.5g,加热回流20min.热过滤,于冰箱中冷却析晶.抽滤,滤饼干燥得西尼地平83.7g,收率85%,mp106~108ºC.
点击显示

西尼地平海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

西尼地平文献

Preparation, characterization and tableting of cilnidipine solid dispersions.

Pak. J. Pharm. Sci. 26(3) , 629-36, (2013)

Solid dispersion technique has been developed many years for improving solubility of water-insoluble drugs, aiming to achieve a better oral bioavailability. However, this technique exhibits many incon...

The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.

Sci. Rep. 5 , 14086, (2015)

The Farnesoid X receptor (FXR) regulates bile salt, glucose and cholesterol homeostasis by binding to DNA response elements, thereby activating gene expression (direct transactivation). FXR also inhib...

Effects of cilnidipine on sympathetic outflow and sympathetic arterial pressure and heart rate regulations in rats.

Life Sci. 92(24-26) , 1202-7, (2013)

Cilnidipine is a unique Ca(2+) channel blocker that inhibits both L-type and N-type Ca(2+) channels. The present study aimed to assess the effects of intravenous cilnidipine on sympathetic outflow and...


更多文献

相关药品：

推荐生产厂家/供应商：

公司名：山东铂源药业有限公司

区域：济南市历城区

价格：
￥需询单/1kg

联系人：王爱秋

产品详情：西尼地平

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：Cilnidipine

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥1489.0/100mg ￥539.0/1g ￥489.0/25mg ￥需询单/1g

联系人：李先生

产品详情：Cilnidipine

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥129.9/1g ￥3822.9/100g ￥1476.9/25g ￥438.9/5g

联系人：阿拉丁李高志

产品详情：西尼地平

公司名：上海创赛科技有限公司

区域：上海市嘉定区

价格：
￥137.0/1g ￥459.0/5g ￥1540.0/25g ￥3988.0/100g

联系人：夏言

产品详情：[Perfemiker]Cilnidipine,≥99%

查看所有供应商请点击：

西尼地平供应商

相关化合物

【西尼地平】化源网提供西尼地平CAS号132203-70-4，西尼地平MSDS及其说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。CAS号查询西尼地平上化源网，专业又轻松。>>电脑版：西尼地平

标题：西尼地平_MSDS_用途_密度_西尼地平CAS号【132203-70-4】_化源网 地址：https://m.chemsrc.com/mip/cas/132203-70-4_832363.html